Response and Resistance to BCR-ABL1-Targeted Therapies
Oregon Health & Science University
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
501
total citations
- FWCI
- 35.28
- Percentile
- 100%
- References
- 157
Citations per year
Authors
3Topics & keywords
Topics
Keywords
- Imatinib
- Tyrosine-kinase inhibitor
- Medicine
- Tyrosine kinase
- Myeloid leukemia
- Imatinib mesylate
- Cancer research
- Dasatinib
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.